About Simon Barnett
Simon joined ARK as a thematic analyst on the Genomic Revolution team in October 2018. His focus is on molecular diagnostics, next generation DNA sequencing, nano-biotechnology, microfluidics, and tissue constructs. Prior to working for ARK, Simon was a finance and operations intern at Aditus Holdings—a financial technology company based in Mexico City. Previously, Simon was an engineering intern at Tissue Analytics—a software firm that utilizes computer vision and machine learning to analyze chronic wounds. Simon graduated from the Johns Hopkins University in 2018 with a Bachelor of Science in Chemical and Biomolecular Engineering focused on Molecular and Cellular Bioengineering.
Research by Simon Barnett
August 29, 2019 | by Simon Barnett | Health
The Human Genome Project in 2003 inspired the dream of precision medicine and turned DNA into mainstream conversation. It also gave rise to next-generation DNA sequencing (NGS), one of the most transformative technology platforms in history. Despite the growing clinical utility of sequencing, most people still associate genetic analysis more with ancestry services than with […]May 15, 2019 | by Simon Barnett | Health
Conventional guidelines for monitoring the recurrence of cancer involve routine physical exams and medical imaging. Recurrent tumors often are aggressive, especially if they appear in locations different from those in the original diagnoses. Yet, while PET and CT scans can surface important information about existing tumors, they rarely detect emerging tumors which, with time, can […]March 13, 2019 | by Simon Barnett | HealthMentioned Companies: GH
Next-generation DNA sequencing (“NGS”) is creating a new wave of diagnostic tests for cancer. The level of detail offered by NGS tools is helping researchers make important connections between the biology of tumors and the successful treatment of cancer. Cancer is a dynamic and elusive disease. Its genetic profile mutates over time, sometimes in response […]